



## **Table of Contents**

Study Purpose	3
Summary	3
Entire Plan	3
Table A – ACLA Entire Plan Summary Table	∠
Encounter Data Analysis	
Summary Charts	<del>(</del>
Data Issues and Recommendations	
Value-Added Services (VAS)	10
Monthly Tables	13
Entire Plan	13
Southeastrans	14
Avesis Vision	15
Avesis Dental	16
PerformRx (Pharmacy)	17
Prime Therapeutics (Pharmacy)	18
Non-Vendor	19
Appendix A: VAS Monthly Tables	20
Entire Plan VAS	20
Southeastrans VAS (NEMT)	21
Avesis Vision VAS	22
Avesis Dental VAS	23
Non-Vendor VAS	24
Appendix B: Definitions and Acronyms	25
Appendix C: Analysis	27
Appendix D: Data Analysis Assumptions	28



## **Study Purpose**

Louisiana Department of Health (LDH) engaged Myers and Stauffer LC to analyze Healthy Louisiana encounter data that has been submitted by the managed care organizations (MCO) to Louisiana's fiscal agent contractor (FAC), Gainwell, and complete a comparison of the encounters to cash disbursement journals provided by each MCO. For purposes of this analysis, "encounter data" are claims that have been paid by AmeriHealth Caritas Louisiana (ACLA) or delegated vendors (e.g., vision and pharmacy) to health care providers that have provided health care services to members enrolled with the MCO. Encounter data is submitted to LDH via the FAC for LDH's use in rate setting, federal reporting, program management and oversight, tracking, accounting, ad hoc analyses, and other activities.

LDH requested that, for this study, we estimate the percentage of each MCO delegated vendor paid encounters that appear to be included in the FAC's database. This analysis includes these percentages for the entire plan, as well as separate vision, non-emergency medical transportation (NEMT), dental value-added service (VAS), and pharmacy delegated vendor encounters paid during the reporting period. We have also included the percentages for total non-vendor MCO paid encounters.

Our work was performed in accordance with American Institute of Certified Public Accountants (AICPA) professional standards for consulting engagements. We were not engaged to, nor did we perform, an audit, examination, or review services; accordingly, we express no opinion or conclusion related to the procedures performed or the information and documentation we reviewed. In addition, our engagement was not specifically designed for, and should not be relied on, to disclose errors, fraud, or other illegal acts that may exist.

The results of our engagement and this report are intended only for the internal use of the LDH and should not be used for any other purpose.

## **Summary**

#### **Entire Plan**

LDH requested that, for this study, we review the plan's paid encounters to determine if the paid encounters meet the state contract completeness range of **99 percent to 100 percent** when compared to the cash disbursement journal (CDJ) files that are submitted by the MCO. The new pharmacy vendor, Prime Therapeutics, effective October 28, 2023, has a state contract completeness range of 97 percent to 100 percent. The encounters and CDJ file utilized in this study met the following criteria:

- Encounter and CDJ transactions were paid within the reporting period of **November 1, 2022** through October 31, 2024.
- Encounters were received and accepted by the FAC and transmitted to Myers and Stauffer LC through **November 26, 2024.**
- Table A on page 4 contains ACLA cumulative completion totals and percentages over report period, prior contract period (November 1, 2022 through December 31, 2022) with 97 percent to 100 percent state contract completeness range, as well as current contract period (January 1, 2023 through October 31, 2024).



#### Table A – ACLA Entire Plan Summary Table

# Table A — ACLA Cumulative Completion Totals and Percentages Measurement Period (November 2022 – October 2024)

	measurement i enou (November 2022 – October 2024)												
				De	elegated Vendor								
Description	Entire Plan	Non-Vendor	Avesis Vision	Southeastrans (NEMT)	Avesis Dental	PerformRx (Pharmacy)	Prime Therapeutics (Pharmacy)						
Encounter Total (FAC reported)	\$2,032,493,611	\$1,318,154,648	\$129,991	\$25,034,009	\$444,414	\$371,092,969	\$317,637,580						
Total Encounter Adjustments (\$)	(\$111,515,984)	(\$71,529,667)	(\$11,073)	(\$292,117)	(\$15,427)	(\$33,343,856)	(\$6,323,844)						
Total Encounter Adjustments (%)	-5.48%	-5.42%	-8.51%	-1.16%	-3.47%	-8.98%	-1.99%						
Net Encounter Total	\$1,920,977,627	\$1,246,624,980	\$118,918	\$24,741,892	\$428,987	\$337,749,113	\$311,313,736						
CDJ Total	\$1,926,318,027	\$1,249,195,606	\$77,184	\$24,679,789	\$433,986	\$339,052,711	\$312,878,751						
Variance	(\$5,340,400)	(\$2,570,626)	\$41,734	\$62,104	(\$4,999)	(\$1,303,598)	(\$1,565,015)						
Completion (%)	99.72%	99.79%	154.07%	100.25%	98.84%	99.61%	99.49%						
100% Limited Completion* (%)	99.71%	N/A	100.00%	100.00%	N/A	N/A	N/A						
Minimum Completeness (%)	٨			97.00%									
Non-Compliant (%)	٨	N/A	54.07%	0.25%	-0.16%	N/A	N/A						
		Prior Contract Perio	od (November 2022	2 – December 2022	2)								
Completion (%)	99.76%	101.36%	146.10%	110.28%	100.03%	96.76%	N/A						
100% Limited Completion* (%)	98.79%	100.00%	100.00%	100.00%	100.00%	N/A	N/A						
Minimum Completeness (%)				97.00%									
Non-Compliant (%)	N/A	1.36%	46.10%	10.28%	0.03%	-0.24%	N/A						
		Current Contract P	eriod (January 202	23 – October 2024)	)								
Completion (%)	99.71%	99.66%	160.13%	99.37%	95.58%	100.20%	99.49%						
100% Limited Completion* (%)	99.68%	N/A	100.00%	N/A	N/A	100.00%	N/A						
Minimum Completeness (%)	۸			99.00%			97.00%						
Non-Compliant (%)	٨	N/A	60.13%	N/A	-3.42%	0.20%	N/A						

<sup>\*</sup> To avoid overstating the Entire Plan results in situations where an individual vendor's cumulative completion percentage exceeds 100 percent, we have decreased the Entire Plan encounter totals by the total variance in comparison to the CDJ. Please see Appendix B for more information on the limited completion percentage.

<sup>^</sup> The Entire Plan Minimum Completeness and Non-Compliant percentages cannot be stated since the new single PBM, Prime Therapeutics, has a minimum threshold of 97 percent which differs from the other delegated vendors that all have a 99 percent minimum threshold.



#### **Encounter Data Analysis**

For this study, Myers and Stauffer analyzes the encounter data that is submitted by the MCO to the FAC and loaded into the FAC Medicaid Management Information System (MMIS). Encounters submitted by the MCO that were rejected by the FAC for errors in submission or other reasons are not transmitted to Myers and Stauffer.

Furthermore, Myers and Stauffer analyzes the encounter data from the FAC MMIS and makes the following adjustments. Table B below outlines the impact of applying these encounter analysis adjustments to the encounter paid amounts, when compared to the raw data received.

- 1. The payment amounts associated with denied encounters are identified as zero dollars in the encounter reconciliation analysis since they bear no impact on cash disbursements.
- 2. We identified potential duplicate encounters using our encounter review logic. Based on a comparison to the CDJ files, we noted some of these potential duplicates appear to be partial payments, some are actual duplicate submissions, and some are replacement encounters without a matching void. At the direction of LDH, we have attempted to adjust our totals to reflect the actual payment made and have removed duplicate payment amounts from our analysis.

Description	Encounter Count	Paid Amount	Paid Amount (% of Total*)
Total Encounter Amount (FAC Reported)	32,868,430	\$2,032,493,611	100.00%
Adjustment Type			
State System Denied	(1,064,180)	(\$82,377,044)	-4.05%
Health Plan Denied	(7,610,944)	(\$27,384,260)	-1.34%
Calculated Void	0	\$0	0.00%
Duplicate	(24,029)	(\$1,754,681)	-0.08%
Total Adjustments Made	(8,699,153)	(\$111,515,984)	-5.48%
Net Encounter Amounts	24,169,277	\$1,920,977,627	94.52%

<sup>\*</sup> Due to rounding, the sum of the displayed percentages in this report may not add up to the total.



#### **Summary Charts**

#### Chart 1. Entire Plan CDJ and Encounter Totals by Paid Month





Chart 2. Entire Plan Completion Percentage by Paid Month





#### **Data Issues and Recommendations**

During this analysis, Myers and Stauffer identified potential data issues that may impact the completion percentages for ACLA. Section A details issues related to non-compliant cumulative completion percentages, while Section B notes outstanding data issues that ACLA may need to work to identify and resolve.

Please reference Tables 1 through 7 for ACLA reconciliation period tables. These tables contain detailed reconciliation totals, completion percentages, and encounter analysis adjustments.

#### Section A: Data issues potentially impacting compliance:

- 1. Southeastrans (Table 2): The overall cumulative completion percentage is out of compliance at 100.25 percent. There are eight months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are three months where the monthly completion percentages are above the 100 percent threshold.
  - The low completion percentages for November 2022, January 2023, February 2023, and April 2023 appear to be due to encounters appearing in different months than the corresponding CDJ transactions, state system denied encounters, and missing encounters.
  - The percentages above 100 percent for December 2022 and March 2023 appear to be
    due to a combination of void encounter transactions appearing in an earlier month than
    the corresponding CDJ transactions and encounter transaction amounts not matching
    with the corresponding CDJ transaction amounts.

**We recommend** ACLA work with Southeastrans, LDH, and Gainwell to identify and correct any CDJ file and/or encounter data submission issues.

- 2. Avesis Vision (Table 3): The overall cumulative completion percentage is out of compliance at 154.07 percent. There are two months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are ten months where the monthly completion percentages are above the 100 percent threshold. Avesis Vision became an inactive vendor as of September 1, 2022.
  - The low completion percentage in July 2023 may be explained by missing CDJ transactions.
  - The high completion percentages may be due to void encounter transactions appearing
    in different months from their corresponding CDJ void transactions, and encounter
    transaction amounts not matching with the corresponding CDJ transaction amounts.

**We recommend** ACLA work with Avesis Vision, LDH, and Gainwell to identify and correct any CDJ file and/or encounter data submission issues.



- **3. Avesis Dental** (Table 4): The overall cumulative completion percentage is out of compliance at 98.84 percent. There are nine months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are five months where the monthly completion percentages are above the 100 percent threshold. Avesis Dental became an inactive vendor as of January 1, 2023.
  - The low completion percentage in January 2023 appears to be due to encounter transaction amounts not matching with the corresponding CDJ transaction amounts.
  - The low completion percentage in February 2023 appears to be due to system denied encounters and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.
  - The low completion percentages in August 2023 and November 2023 appear to be due to state system denied encounters.
  - The high completion percentages in March 2023 through May 2023 and December 2023 appear to be due to encounter transaction amounts not matching with the corresponding CDJ transaction amounts.

**We recommend** ACLA work with Avesis Dental, LDH, and Gainwell to identify and correct any CDJ file and/or encounter data submission issues.

## Section B: Data issues not currently impacting compliance:

- 4. PerformRx (Table 5): The overall cumulative completion percentage is in compliance at 99.61 percent. There are fourteen months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are nine months where the monthly completion percentages are above the 100 percent threshold. PerformRx became an inactive vendor as of October 28, 2023.
  - These percentages may be explained by void encounter transactions appearing in different months from their corresponding CDJ transactions and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.

**We recommend** ACLA work with PerformRx, LDH, and Gainwell to identify and correct any CDJ file and/or encounter data submission issues

**5. Prime Therapeutics** (Table 6): The overall cumulative completion percentage is in compliance at 99.49 percent. There is one month where the monthly completion percentage is below the 97



percent threshold. Additionally, there are six months where the monthly completion percentage is above the 100 percent threshold.

- The low completion percentage in November 2023 appears to be due to void CDJ transactions appearing in later months than the corresponding void encounter transactions.
- The high completion percentages in February 2024, March 2024, and July 2024 appear to be due to void encounter transactions appearing in earlier months than the corresponding void CDJ transactions.

**We recommend** ACLA work with Prime Therapeutics, LDH, and Gainwell to identify and correct any CDJ file and/or encounter data submission issues.

- **6. Non-Vendor** (Table 7): The overall cumulative completion percentage is in compliance at 99.79 percent. There are ten months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are nine months where the monthly completion percentages are above the 100 percent threshold.
  - The low completion percentages for February 2023, June 2023, July 2023, September 2023, October 2023, January 2024, February 2024, and April 2024 appear to be due to state system denied encounters and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.
  - The high completion percentages appear to be due to encounter transactions appearing in different months from their corresponding CDJ transactions and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.

**We recommend** ACLA work with LDH and Gainwell to identify and correct any CDJ file and/or encounter data submission issues.



#### **Value-Added Services (VAS)**

Value-added services are included in the MCO's vision, dental, and non-vendor CDJ and encounter totals. VAS CDJ data is identified based on the activity type field of the CDJ files received from the MCO and VAS encounter data is identified based on the first two characters of the Plan ICN field.

Below is a summary of the cumulative completion percentages for all delegated vendor and non-vendor paid VAS encounters submitted to Gainwell, for the reporting period. The VAS CDJ and encounter totals in the table below are included in the entire plan, non-vendor and delegated vendor completion percentage tables as well.

Table C — Ame	riHealth Caritas Louisian	a VAS Cumulative C	ompletion Totals a	nd Percentages	
				Delegated Vendo	or
Description	Entire Plan VAS	Non-Vendor VAS	Avesis Vision VAS	Avesis Dental VAS	Southeastrans VAS (NEMT)
Encounter Total (FAC reported)	\$8,048,675	\$7,120,257	\$24,900	\$444,414	\$459,103
Total Encounter Adjustments (\$)	(\$297,511)	(\$277,327)	(\$2,102)	(\$15,427)	(\$2,655)
Total Encounter Adjustments (%)	-3.69%	-3.89%	-8.44%	-3.47%	-0.57%
Net Encounter Total	\$7,751,163	\$6,842,931	\$22,799	\$428,987	\$456,447
CDJ Total	\$8,028,365	\$7,129,832	\$23,186	\$433,986	\$441,361
Variance	(\$277,202)	(\$286,901)	(\$387)	(\$4,999)	\$15,086
Completion (%)	96.54%	95.97%	98.32%	98.84%	103.41%
100% Limited Completion (%)	96.35%	N/A	N/A	N/A	100.00%
Minimum Completeness (%)			99.00%		
Non-Compliant (%)	-2.46%	-3.03%	-0.68%	-0.16%	3.41%

<sup>\*</sup> To avoid overstating the VAS Entire Plan results in situations where an individual vendor's cumulative completion percentage exceeds 100 percent, we decrease the Entire Plan encounter totals by the total variance in comparison to the CDJ. Please see Appendix B for more information on the limited completion percentage.



#### Potential VAS data issues:

- 1. **Southeastrans VAS** (Table 2V): The cumulative completion percentage for Southeastrans VAS is out of compliance at 103.41 percent. There are four months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are eight months where the monthly completion percentages are above the 100 percent threshold.
  - The low completion percentage in March 2023 appears to be due to Southeastrans VAS encounters possibly showing as non-VAS instead of VAS.
  - The low completion percentage in April 2023 appears to be due to missing encounter transactions and encounter transactions occurring in an earlier month than the corresponding CDJ transactions.
  - The high completion percentages in June 2023 and December 2023 appear to be due to Southeastrans non-VAS encounters possibly showing as VAS instead of non-VAS and/or Southeastrans VAS CDJs possibly showing as non-VAS instead of VAS.
- Avesis Vision VAS (Table 3V): The cumulative completion percentage for Avesis Vision VAS is out
  of compliance at 98.32 percent. There are four months where the monthly completion
  percentages are below the 99 percent threshold and six months where the monthly completion
  percentages are above the 100 percent threshold. Avesis Vision became an inactive vendor as of
  September 1, 2022.
  - The high completion percentages appear to be due to encounter transaction amounts not matching with the corresponding CDJ transaction amounts.
  - The low completion percentages in May 2023 and July 2023 appear to be due to Avesis Vision VAS encounters possibly appearing as non-VAS instead of VAS.
- 3. **ACLA's Non-Vendor VAS** (Table 5V): The cumulative completion percentage for Non-Vendor VAS is out of compliance at 95.97 percent. There are twenty-one months where the monthly completion percentages are below the 99 percent threshold. Additionally, there are two months where the monthly completion percentages are above the 100 percent threshold.
  - The low completion percentages for November 2022 through September 2023, November 2023 through May 2024, September 2024, and October 2024 may be explained by encounter transactions occurring in different months than the corresponding CDJ transactions and encounter transaction amounts not matching with the corresponding CDJ transaction amounts.
  - The high completion percentage in October 2023 appears to be due to Non-Vendor non-VAS encounters possibly appearing as VAS instead of non-VAS.



• The high completion percentage in August 2024 appears to be due to encounter transaction amounts not matching with the corresponding CDJ transaction amounts.



# **Monthly Tables**

#### **Entire Plan**

			Percentage of				Monthly
Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Completion Percentage
November 2022	\$85,096,572	-\$4,146,426	-4.87%	\$80,950,146	\$77,726,815	\$3,223,331	104.14%
December 2022	\$79,959,419	-\$6,260,337	-7.82%	\$73,699,082	\$77,280,013	(\$3,580,931)	95.36%
January 2023	\$93,614,676	-\$8,177,619	-8.73%	\$85,437,057	\$83,408,503	\$2,028,554	102.43%
February 2023	\$89,216,990	-\$6,656,742	-7.46%	\$82,560,248	\$85,351,223	(\$2,790,975)	96.73%
March 2023	\$103,785,395	-\$8,965,658	-8.63%	\$94,819,738	\$95,565,219	(\$745,482)	99.21%
April 2023	\$84,677,744	-\$4,685,231	-5.53%	\$79,992,512	\$79,669,822	\$322,691	100.40%
May 2023	\$93,557,737	-\$7,480,802	-7.99%	\$86,076,935	\$84,179,537	\$1,897,398	102.25%
June 2023	\$86,451,088	-\$3,979,261	-4.60%	\$82,471,827	\$87,486,896	(\$5,015,070)	94.26%
July 2023	\$85,358,591	-\$11,331,891	-13.27%	\$74,026,700	\$76,174,525	(\$2,147,825)	97.18%
August 2023	\$90,033,456	-\$8,591,485	-9.54%	\$81,441,971	\$78,694,692	\$2,747,280	103.49%
September 2023	\$89,879,562	-\$8,132,560	-9.04%	\$81,747,002	\$88,711,398	(\$6,964,396)	92.14%
October 2023	\$80,921,984	-\$7,081,860	-8.75%	\$73,840,124	\$82,917,869	(\$9,077,745)	89.05%
November 2023	\$84,644,497	-\$4,310,130	-5.09%	\$80,334,367	\$80,958,920	(\$624,553)	99.22%
December 2023	\$81,783,856	-\$3,195,561	-3.90%	\$78,588,295	\$77,799,518	\$788,778	101.01%
January 2024	\$90,273,083	-\$3,186,678	-3.53%	\$87,086,405	\$81,079,122	\$6,007,283	107.40%
February 2024	\$69,457,995	-\$2,282,881	-3.28%	\$67,175,114	\$67,954,373	(\$779,259)	98.85%
March 2024	\$73,223,119	-\$1,738,975	-2.37%	\$71,484,145	\$71,086,238	\$397,906	100.55%
April 2024	\$79,426,666	-\$1,726,204	-2.17%	\$77,700,462	\$79,152,856	(\$1,452,393)	98.16%
May 2024	\$80,118,826	-\$2,051,762	-2.56%	\$78,067,064	\$78,722,337	(\$655,274)	99.16%
June 2024	\$82,724,939	-\$1,925,655	-2.32%	\$80,799,284	\$80,589,720	\$209,564	100.26%
July 2024	\$80,173,985	-\$1,537,626	-1.91%	\$78,636,359	\$78,849,859	(\$213,500)	99.72%
August 2024	\$79,612,599	-\$1,347,803	-1.69%	\$78,264,796	\$74,726,771	\$3,538,026	104.73%
September 2024	\$78,363,498	-\$1,201,465	-1.53%	\$77,162,033	\$76,386,706	\$775,327	101.01%
October 2024	\$90,137,333	-\$1,521,372	-1.68%	\$88,615,961	\$81,845,096	\$6,770,865	108.27%
Cumulative Totals	\$2,032,493,611	(\$111,515,984)	-5.48%	\$1,920,977,627	\$1,926,318,027	(\$5,340,400)	99.72%
00% Limited Cumulative Total				\$1,920,873,788.91	\$1,926,318,027	(\$5,444,238)	99.71%
Total					Minii	num Completeness (%)	See Table A
						Non-Compliant	See Table A



#### Southeastrans

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$813,615	(\$1,649)	-0.20%	\$811,967	\$909,553	(\$97,587)	89.27%
December 2022	\$1,396,677	(\$9,885)	-0.70%	\$1,386,792	\$1,084,235	\$302,558	127.90%
January 2023	\$841,863	(\$67,543)	-8.02%	\$774,320	\$833,166	(\$58,846)	92.93%
February 2023	\$1,023,484	(\$94,620)	-9.24%	\$928,864	\$958,687	(\$29,824)	96.88%
March 2023	\$1,358,441	(\$11,571)	-0.85%	\$1,346,870	\$1,250,013	\$96,858	107.74%
April 2023	\$875,866	(\$4,672)	-0.53%	\$871,194	\$892,488	(\$21,293)	97.61%
May 2023	\$907,108	(\$6,247)	-0.68%	\$900,861	\$907,612	(\$6,751)	99.25%
June 2023	\$1,293,317	(\$5,613)	-0.43%	\$1,287,703	\$1,296,140	(\$8,436)	99.34%
July 2023	\$995,598	(\$7,119)	-0.71%	\$988,479	\$992,866	(\$4,387)	99.55%
August 2023	\$1,116,799	(\$6,256)	-0.56%	\$1,110,544	\$1,124,865	(\$14,321)	98.72%
September 2023	\$1,433,998	(\$7,853)	-0.54%	\$1,426,145	\$1,443,438	(\$17,293)	98.80%
October 2023	\$995,844	(\$5,993)	-0.60%	\$989,851	\$999,309	(\$9,459)	99.05%
November 2023	\$1,012,694	(\$7,710)	-0.76%	\$1,004,984	\$1,015,754	(\$10,770)	98.93%
December 2023	\$1,178,249	(\$7,577)	-0.64%	\$1,170,672	\$1,184,727	(\$14,055)	98.81%
January 2024	\$790,549	(\$13,248)	-1.67%	\$777,301	\$782,466	(\$5,165)	99.33%
February 2024	\$871,985	(\$1,727)	-0.19%	\$870,258	\$875,318	(\$5,060)	99.42%
March 2024	\$1,115,551	(\$1,312)	-0.11%	\$1,114,239	\$1,113,306	\$933	100.08%
April 2024	\$924,036	(\$2,876)	-0.31%	\$921,160	\$923,574	(\$2,414)	99.73%
May 2024	\$1,189,340	(\$3,261)	-0.27%	\$1,186,079	\$1,189,780	(\$3,701)	99.68%
June 2024	\$925,875	(\$5,596)	-0.60%	\$920,279	\$927,973	(\$7,694)	99.17%
July 2024	\$877,323	(\$3,751)	-0.42%	\$873,572	\$878,248	(\$4,676)	99.46%
August 2024	\$1,177,202	(\$8,483)	-0.72%	\$1,168,719	\$1,179,853	(\$11,135)	99.05%
September 2024	\$850,705	(\$3,207)	-0.37%	\$847,498	\$851,730	(\$4,232)	99.50%
October 2024	\$1,067,890	(\$4,349)	-0.40%	\$1,063,542	\$1,064,688	(\$1,147)	99.89%
Cumulative Totals	\$25,034,009	(\$292,117)	-1.16%	\$24,741,892	\$24,679,789	\$62,104	100.25%
00% Limited Cumulative Total				\$24,679,789	\$24,679,789	\$0	100.00%
					Mini	mum Completeness (%)	99.00%
						Non-Compliant	0.25%



#### **Avesis Vision**

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$29,197	(\$1,495)	-5.11%	\$27,702	\$21,964	\$5,739	126.12%
December 2022	\$26,711	(\$5,675)	-21.24%	\$21,035	\$11,395	\$9,641	184.60%
January 2023	\$13,728	(\$957)	-6.97%	\$12,771	\$3,598	\$9,172	354.88%
February 2023	\$7,603	(\$1,215)	-15.97%	\$6,388	\$5,737	\$652	111.35%
March 2023	\$14,424	(\$200)	-1.38%	\$14,224	\$11,463	\$2,761	124.08%
April 2023	\$5,702	(\$928)	-16.27%	\$4,774	\$1,885	\$2,889	253.26%
May 2023	\$26,168	(\$602)	-2.30%	\$25,566	\$19,353	\$6,213	132.10%
June 2023	\$4,197	\$0	0.00%	\$4,197	\$3,696	\$501	113.56%
July 2023	\$323	\$0	0.00%	\$323	(\$3,216)	\$3,539	-10.04%
August 2023	\$1,068	\$0	0.00%	\$1,068	\$790	\$278	135.25%
September 2023	\$0	\$0	N/A	\$0	(\$102)	\$102	0.00%
October 2023	\$870	\$0	0.00%	\$870	\$623	\$248	139.75%
November 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
July 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
Cumulative Totals	\$129,991	(\$11,073)	-8.51%	\$118,918	\$77,184	\$41,734	154.07%
00% Limited Cumulative Total				\$77,184	\$77,184	\$0	100.00%
					Minii	num Completeness (%)	99.00%
						Non-Compliant	54.07%



#### **Avesis Dental**

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$188,059	(\$5,328)	-3%	\$182,731	\$183,089	(\$358)	99.80%
December 2022	\$136,918	(\$1,082)	-1%	\$135,835	\$135,378	\$457	100.33%
January 2023	\$51,681	(\$3,428)	-7%	\$48,253	\$50,836	(\$2,583)	94.91%
February 2023	\$19,190	(\$4,918)	-26%	\$14,272	\$14,680	(\$408)	97.21%
March 2023	\$7,047	(\$410)	-5.81%	\$6,637	\$5,661	\$975	117.22%
April 2023	\$9,443	(\$145)	-1.53%	\$9,299	\$5,076	\$4,223	183.19%
May 2023	\$3,452	(\$117)	-3.39%	\$3,334	\$3,133	\$202	106.43%
June 2023	\$14,179	\$0	0.00%	\$14,179	\$14,348	(\$169)	98.82%
July 2023	\$8,744	\$0	0.00%	\$8,744	\$8,910	(\$167)	98.12%
August 2023	\$0	\$0	N/A	\$0	\$6,073	(\$6,073)	0.00%
September 2023	\$996	\$0	0.00%	\$996	\$1,075	(\$79)	92.64%
October 2023	\$905	\$0	0.00%	\$905	\$942	(\$38)	95.98%
November 2023	\$2,291	\$0	0.00%	\$2,291	\$3,483	(\$1,193)	65.75%
December 2023	\$1,224	\$0	0.00%	\$1,224	\$768	\$456	159.36%
January 2024	\$288	\$0	0.00%	\$288	\$532	(\$244)	54.10%
February 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
July 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
Cumulative Totals	\$444,414	(\$15,427)	-3.47%	\$428,987	\$433,986	(\$4,999)	98.84%
00% Limited Cumulative Total							N/A
Total					Mini	mum Completeness (%)	99.00%
						Non-Compliant	-0.16%



## PerformRx (Pharmacy)

		Table 5 — Ameril	lealth Caritas Loui	siana PerformRx (Pharma	icy)		
Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$30,637,996	(\$2,539,416)	-8.28%	\$28,098,580	\$25,341,957	\$2,756,623	110.87%
December 2022	\$30,324,358	(\$2,442,843)	-8.05%	\$27,881,515	\$32,512,059	(\$4,630,543)	85.75%
January 2023	\$30,152,342	(\$2,781,618)	-9.22%	\$27,370,725	\$25,146,350	\$2,224,375	108.84%
February 2023	\$29,294,521	(\$2,447,851)	-8.35%	\$26,846,670	\$27,018,621	(\$171,951)	99.36%
March 2023	\$38,768,563	(\$5,393,550)	-13.91%	\$33,375,012	\$33,924,875	(\$549,863)	98.37%
April 2023	\$29,990,213	(\$2,698,109)	-8.99%	\$27,292,104	\$26,285,745	\$1,006,359	103.82%
May 2023	\$31,080,040	(\$2,478,761)	-7.97%	\$28,601,279	\$26,332,631	\$2,268,648	108.61%
June 2023	\$30,933,802	(\$1,434,076)	-4.63%	\$29,499,726	\$33,512,782	(\$4,013,056)	88.02%
July 2023	\$29,451,674	(\$2,293,523)	-7.78%	\$27,158,151	\$25,446,935	\$1,711,216	106.72%
August 2023	\$31,682,901	(\$2,080,159)	-6.56%	\$29,602,742	\$26,176,740	\$3,426,002	113.08%
September 2023	\$29,660,457	(\$2,908,419)	-9.80%	\$26,752,038	\$32,478,388	(\$5,726,350)	82.36%
October 2023	\$21,073,643	(\$3,268,237)	-15.50%	\$17,805,407	\$25,657,137	(\$7,851,730)	69.39%
November 2023	\$112,764	(\$36,915)	-32.73%	\$75,849	(\$837,747)	\$913,596	-9.05%
December 2023	\$393,772	(\$344,150)	-87.39%	\$49,622	(\$2,475)	\$52,097	-2004.96%
January 2024	\$7,406,741	(\$102,377)	-1.38%	\$7,304,364	\$66,526	\$7,237,838	10979.64%
February 2024	\$454	(\$357)	-78.65%	\$97	(\$10,517)	\$10,614	-0.92%
March 2024	\$61,492	(\$60,439)	-98.28%	\$1,052	(\$3,444)	\$4,497	-30.55%
April 2024	\$2,103	(\$691)	-32.86%	\$1,412	(\$43)	\$1,455	-3305.75%
May 2024	\$17,225	(\$14,485)	-84.09%	\$2,740	(\$23,796)	\$26,536	-11.51%
June 2024	\$12,308	\$0	0.00%	\$12,308	\$12,109	\$199	101.63%
July 2024	\$33,896	(\$17,880)	-52.74%	\$16,017	\$13,102	\$2,915	122.24%
August 2024	\$1,703	\$0	0.00%	\$1,703	\$2,744	(\$1,041)	62.07%
September 2024	\$0	\$0	N/A	\$0	\$933	(\$933)	0.00%
October 2024	\$0	\$0	N/A	\$0	\$1,098	(\$1,098)	0.00%
Cumulative Totals	\$371,092,969	(\$33,343,856)	-8.98%	\$337,749,113	\$339,052,711	(\$1,303,598)	99.61%
00% Limited Cumulative Total							N/A
i otal					Minii	num Completeness (%)	99.00%
						Non-Compliant	N/A



## **Prime Therapeutics (Pharmacy)**

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2022	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
July 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
November 2023	\$25,341,825	(\$1,536,910)	-6.06%	\$23,804,915	\$25,438,335	(\$1,633,420)	93.57%
December 2023	\$28,166,745	(\$1,363,933)	-4.84%	\$26,802,812	\$26,827,363	(\$24,551)	99.90%
January 2024	\$29,657,092	(\$1,231,209)	-4.15%	\$28,425,883	\$28,345,456	\$80,427	100.28%
February 2024	\$26,022,444	(\$947,779)	-3.64%	\$25,074,664	\$24,657,756	\$416,909	101.69%
March 2024	\$24,845,178	(\$367,996)	-1.48%	\$24,477,182	\$24,256,215	\$220,967	100.91%
April 2024	\$29,137,558	(\$162,924)	-0.55%	\$28,974,634	\$29,578,531	(\$603,897)	97.95%
May 2024	\$25,015,580	(\$133,478)	-0.53%	\$24,882,102	\$25,179,941	(\$297,839)	98.81%
June 2024	\$24,778,761	(\$150,827)	-0.60%	\$24,627,935	\$24,652,582	(\$24,647)	99.90%
July 2024	\$29,809,507	(\$218,685)	-0.73%	\$29,590,822	\$29,382,175	\$208,647	100.71%
August 2024	\$23,537,688	(\$85,609)	-0.36%	\$23,452,079	\$23,563,626	(\$111,547)	99.52%
September 2024	\$22,404,923	(\$67,511)	-0.30%	\$22,337,413	\$22,238,420	\$98,993	100.44%
October 2024	\$28,920,278	(\$56,984)	-0.19%	\$28,863,294	\$28,758,351	\$104,942	100.36%
Cumulative Totals	\$317,637,580	(\$6,323,844)	-1.99%	\$311,313,736	\$312,878,751	(\$1,565,015)	99.49%
00% Limited Cumulative Total							N/A
IUlai					Mini	num Completeness (%)	97.00%
						Non-Compliant	N/A



#### Non-Vendor

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$53,427,704	(\$1,598,538)	-2.99%	\$51,829,166	\$51,270,252	\$558,914	101.09%
December 2022	\$48,074,756	(\$3,800,853)	-7.90%	\$44,273,903	\$43,536,946	\$736,957	101.69%
January 2023	\$62,555,062	(\$5,324,073)	-8.51%	\$57,230,989	\$57,374,552	(\$143,564)	99.74%
February 2023	\$58,872,192	(\$4,108,137)	-6.97%	\$54,764,054	\$57,353,498	(\$2,589,444)	95.48%
March 2023	\$63,636,922	(\$3,559,926)	-5.59%	\$60,076,995	\$60,373,208	(\$296,213)	99.50%
April 2023	\$53,796,519	(\$1,981,378)	-3.68%	\$51,815,141	\$52,484,629	(\$669,487)	98.72%
May 2023	\$61,540,969	(\$4,995,075)	-8.11%	\$56,545,895	\$56,916,809	(\$370,914)	99.34%
June 2023	\$54,205,593	(\$2,539,572)	-4.68%	\$51,666,021	\$52,659,930	(\$993,910)	98.11%
July 2023	\$54,902,252	(\$9,031,249)	-16.44%	\$45,871,003	\$49,729,028	(\$3,858,025)	92.24%
August 2023	\$57,232,687	(\$6,505,070)	-11.36%	\$50,727,618	\$51,386,224	(\$658,607)	98.71%
September 2023	\$58,784,111	(\$5,216,289)	-8.87%	\$53,567,822	\$54,788,599	(\$1,220,777)	97.77%
October 2023	\$58,850,722	(\$3,807,630)	-6.46%	\$55,043,091	\$56,259,857	(\$1,216,766)	97.83%
November 2023	\$58,174,924	(\$2,728,595)	-4.69%	\$55,446,328	\$55,339,095	\$107,233	100.19%
December 2023	\$52,043,867	(\$1,479,902)	-2.84%	\$50,563,965	\$49,789,134	\$774,831	101.55%
January 2024	\$52,418,413	(\$1,839,845)	-3.50%	\$50,578,569	\$51,884,141	(\$1,305,573)	97.48%
February 2024	\$42,563,113	(\$1,333,018)	-3.13%	\$41,230,095	\$42,431,817	(\$1,201,722)	97.16%
March 2024	\$47,200,899	(\$1,309,227)	-2.77%	\$45,891,671	\$45,720,162	\$171,510	100.37%
April 2024	\$49,362,969	(\$1,559,712)	-3.15%	\$47,803,256	\$48,650,793	(\$847,537)	98.25%
May 2024	\$53,896,682	(\$1,900,538)	-3.52%	\$51,996,143	\$52,376,413	(\$380,269)	99.27%
June 2024	\$57,007,995	(\$1,769,232)	-3.10%	\$55,238,763	\$54,997,056	\$241,707	100.43%
July 2024	\$49,453,258	(\$1,297,310)	-2.62%	\$48,155,949	\$48,576,334	(\$420,385)	99.13%
August 2024	\$54,896,006	(\$1,253,711)	-2.28%	\$53,642,295	\$49,980,547	\$3,661,748	107.32%
September 2024	\$55,107,870	(\$1,130,748)	-2.05%	\$53,977,122	\$53,295,624	\$681,498	101.27%
October 2024	\$60,149,165	(\$1,460,039)	-2.42%	\$58,689,126	\$52,020,958	\$6,668,168	112.81%
Cumulative Totals	\$1,318,154,648	(\$71,529,667)	-5.42%	\$1,246,624,980	\$1,249,195,606	(\$2,570,626)	99.79%
00% Limited Cumulative Total							N/A
					Minii	num Completeness (%)	99.00%
						Non-Compliant	N/A



# **Appendix A: VAS Monthly Tables**

#### **Entire Plan VAS**

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completio Percentag
November 2022	\$429,652	(\$6,520)	-1.51%	\$423,132	\$428,478	(\$5,346)	98.75%
December 2022	\$388,780	(\$3,311)	-0.85%	\$385,469	\$385,590	(\$121)	99.96%
January 2023	\$389,591	(\$36,907)	-9.47%	\$352,684	\$358,342	(\$5,658)	98.42%
February 2023	\$341,814	(\$45,165)	-13.21%	\$296,649	\$311,620	(\$14,971)	95.19%
March 2023	\$303,864	(\$17,354)	-5.71%	\$286,509	\$325,779	(\$39,270)	87.94%
April 2023	\$308,609	(\$17,315)	-5.61%	\$291,294	\$298,285	(\$6,991)	97.65%
May 2023	\$379,668	(\$25,521)	-6.72%	\$354,147	\$406,240	(\$52,092)	87.17%
June 2023	\$354,829	(\$13,634)	-3.84%	\$341,196	\$311,775	\$29,420	109.43%
July 2023	\$405,416	(\$17,881)	-4.41%	\$387,536	\$403,608	(\$16,073)	96.01%
August 2023	\$360,951	(\$21,603)	-5.98%	\$339,348	\$356,725	(\$17,378)	95.12%
September 2023	\$329,086	(\$9,497)	-2.88%	\$319,590	\$334,812	(\$15,222)	95.45%
October 2023	\$352,642	(\$4,950)	-1.40%	\$347,692	\$339,060	\$8,632	102.54%
November 2023	\$318,610	(\$7,060)	-2.21%	\$311,549	\$334,452	(\$22,903)	93.15%
December 2023	\$313,517	(\$4,622)	-1.47%	\$308,895	\$346,241	(\$37,346)	89.21%
January 2024	\$252,887	(\$2,257)	-0.89%	\$250,630	\$271,585	(\$20,955)	92.28%
February 2024	\$434,612	(\$7,814)	-1.79%	\$426,798	\$434,686	(\$7,888)	98.18%
March 2024	\$215,017	(\$2,052)	-0.95%	\$212,964	\$220,103	(\$7,139)	96.75%
April 2024	\$278,413	(\$2,137)	-0.76%	\$276,276	\$281,538	(\$5,262)	98.13%
May 2024	\$365,278	(\$17,975)	-4.92%	\$347,303	\$361,726	(\$14,423)	96.01%
June 2024	\$310,990	(\$20,983)	-6.74%	\$290,007	\$291,323	(\$1,316)	99.54%
July 2024	\$321,892	(\$8,588)	-2.66%	\$313,303	\$316,923	(\$3,620)	98.85%
August 2024	\$290,765	(\$708)	-0.24%	\$290,056	\$283,583	\$6,473	102.28%
September 2024	\$282,607	(\$2,133)	-0.75%	\$280,474	\$291,789	(\$11,315)	96.12%
October 2024	\$319,185	(\$1,525)	-0.47%	\$317,660	\$334,100	(\$16,440)	95.07%
Cumulative Totals	\$8,048,675	(\$297,511)	-3.69%	\$7,751,163	\$8,028,365	(\$277,202)	96.54%
00% Limited Cumulative Total				\$7,736,077.42	\$8,028,365	(\$292,287)	96.35%
	·	· '			Minim	um Completeness (%)	99.00%
						Non-Compliant	-2.46%



## **Southeastrans VAS (NEMT)**

Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$17,358	\$0	0.00%	\$17,358	\$17,267	\$91	100.52%
December 2022	\$20,738	(\$221)	-1.06%	\$20,518	\$20,167	\$351	101.73%
January 2023	\$17,172	(\$1,302)	-7.58%	\$15,870	\$15,786	\$84	100.53%
February 2023	\$12,817	(\$643)	-5.01%	\$12,174	\$11,951	\$224	101.87%
March 2023	\$15,270	\$0	0.00%	\$15,270	\$42,513	(\$27,242)	35.91%
April 2023	\$40,521	\$0	0.00%	\$40,521	\$41,441	(\$921)	97.77%
May 2023	\$49,863	(\$15)	-0.03%	\$49,848	\$50,381	(\$533)	98.94%
June 2023	\$65,379	(\$37)	-0.05%	\$65,342	\$23,416	\$41,926	279.04%
July 2023	\$33,077	(\$31)	-0.09%	\$33,046	\$33,077	(\$31)	99.90%
August 2023	\$18,083	\$0	0.00%	\$18,083	\$18,117	(\$33)	99.81%
September 2023	\$24,150	(\$8)	-0.03%	\$24,142	\$24,176	(\$34)	99.86%
October 2023	\$19,613	(\$11)	-0.05%	\$19,602	\$19,547	\$55	100.28%
November 2023	\$19,584	(\$142)	-0.72%	\$19,442	\$19,586	(\$144)	99.26%
December 2023	\$21,377	(\$136)	-0.63%	\$21,242	\$19,861	\$1,381	106.95%
January 2024	\$7,499	(\$111)	-1.47%	\$7,389	\$7,422	(\$34)	99.54%
February 2024	\$8,819	\$0	0.00%	\$8,819	\$8,819	\$0	100.00%
March 2024	\$8,994	\$0	0.00%	\$8,994	\$8,994	\$0	100.00%
April 2024	\$6,254	\$0	0.00%	\$6,254	\$6,254	\$0	100.00%
May 2024	\$13,575	\$0	0.00%	\$13,575	\$13,575	\$0	100.00%
June 2024	\$6,777	\$0	0.00%	\$6,777	\$6,777	\$0	100.00%
July 2024	\$6,783	\$0	0.00%	\$6,783	\$6,748	\$35	100.52%
August 2024	\$9,489	\$0	0.00%	\$9,489	\$9,489	\$0	100.00%
September 2024	\$7,527	\$0	0.00%	\$7,527	\$7,615	(\$88)	98.84%
October 2024	\$8,383	\$0	0.00%	\$8,383	\$8,383	\$0	100.00%
Cumulative Totals	\$459,103	(\$2,655)	-0.57%	\$456,447	\$441,361	\$15,086	103.41%
00% Limited Cumulative Total				\$441,361	\$441,361	\$0	100.00%
		·			Minim	um Completeness (%)	99.00%



#### **Avesis Vision VAS**

November 2022 December 2022 January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023	\$8,142 \$6,466 \$1,936 \$1,745 \$3,659 \$1,468 \$1,016 \$420 \$50 \$0	(\$69) (\$1,111) (\$174) (\$447) (\$200) (\$100) \$0 \$0 \$0	-0.85% -17.18% -8.98% -25.64% -5.46% -6.81% 0.00% 0.00% N/A	\$8,072 \$5,355 \$1,762 \$1,297 \$3,459 \$1,368 \$1,016 \$420 \$50	\$8,006 \$2,587 \$1,195 \$1,298 \$3,060 \$431 \$7,326 \$146 (\$854)	\$66 \$2,768 \$566 (\$1) \$399 \$936 (\$6,310) \$274	100.82% 207.01% 147.38% 99.94% 113.04% 317.07% 13.86% 286.86%
January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023	\$1,936 \$1,745 \$3,659 \$1,468 \$1,016 \$420 \$50	(\$174) (\$447) (\$200) (\$100) \$0 \$0 \$0	-8.98% -25.64% -5.46% -6.81% 0.00% 0.00%	\$1,762 \$1,297 \$3,459 \$1,368 \$1,016 \$420	\$1,195 \$1,298 \$3,060 \$431 \$7,326 \$146	\$566 (\$1) \$399 \$936 (\$6,310) \$274	147.38% 99.94% 113.04% 317.07% 13.86%
February 2023  March 2023  April 2023  May 2023  June 2023  July 2023  August 2023  September 2023	\$1,745 \$3,659 \$1,468 \$1,016 \$420 \$50 \$0	(\$447) (\$200) (\$100) \$0 \$0 \$0	-25.64% -5.46% -6.81% 0.00% 0.00%	\$1,297 \$3,459 \$1,368 \$1,016 \$420	\$1,298 \$3,060 \$431 \$7,326 \$146	(\$1) \$399 \$936 (\$6,310) \$274	99.94% 113.04% 317.07% 13.86%
March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023	\$3,659 \$1,468 \$1,016 \$420 \$50 \$0	(\$200) (\$100) \$0 \$0 \$0	-5.46% -6.81% 0.00% 0.00% 0.00%	\$3,459 \$1,368 \$1,016 \$420	\$3,060 \$431 \$7,326 \$146	\$399 \$936 (\$6,310) \$274	113.04% 317.07% 13.86%
April 2023 May 2023 June 2023 July 2023 August 2023 September 2023	\$1,468 \$1,016 \$420 \$50 \$0	(\$100) \$0 \$0 \$0	-6.81% 0.00% 0.00% 0.00%	\$1,368 \$1,016 \$420	\$431 \$7,326 \$146	\$936 (\$6,310) \$274	317.07% 13.86%
May 2023 June 2023 July 2023 August 2023 September 2023	\$1,016 \$420 \$50 \$0	\$0 \$0 \$0	0.00% 0.00% 0.00%	\$1,016 \$420	\$7,326 \$146	(\$6,310) \$274	13.86%
June 2023 July 2023 August 2023 September 2023	\$420 \$50 \$0	\$0 \$0	0.00% 0.00%	\$420	\$146	\$274	
July 2023 August 2023 September 2023	\$50 \$0	\$0	0.00%	·	* -	·	286.86%
August 2023 September 2023	\$0	·		\$50	(\$854)	A	
September 2023		\$0	N/A		(ΨΟΟ-1)	\$904	-5.85%
<u>'</u>	\$0		IN/A	\$0	\$69	(\$69)	0.00%
		\$0	N/A	\$0	\$0	\$0	N/A
October 2023	\$0	\$0	N/A	\$0	(\$79)	\$79	0.00%
November 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
December 2023	\$0	\$0	N/A	\$0	\$0	\$0	N/A
January 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
February 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
July 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
Cumulative Totals	\$24,900	(\$2,102)	-8.44%	\$22,799	\$23,186	(\$387)	98.32%
00% Limited Cumulative Total							N/A
· .	, i				Minim	um Completeness (%)	99.00%



#### **Avesis Dental VAS**

November 2022 December 2022 January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023 December 2023	\$188,059 \$136,918 \$51,681 \$19,190 \$7,047 \$9,443 \$3,452 \$14,179	(\$5,328) (\$1,082) (\$3,428) (\$4,918) (\$410) (\$145)	-2.83% -0.79% -6.63% -25.62% -5.81%	\$182,731 \$135,835 \$48,253 \$14,272	\$183,089 \$135,378 \$50,836	(\$358) \$457 (\$2,583)	99.80%
January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023	\$51,681 \$19,190 \$7,047 \$9,443 \$3,452 \$14,179	(\$3,428) (\$4,918) (\$410)	-6.63% -25.62%	\$48,253	\$50,836	,	
February 2023  March 2023  April 2023  May 2023  June 2023  July 2023  August 2023  September 2023  October 2023  November 2023	\$19,190 \$7,047 \$9,443 \$3,452 \$14,179	(\$4,918) (\$410)	-25.62%			(\$2,583)	04.0451
March 2023     April 2023     May 2023     June 2023     July 2023     August 2023     September 2023     October 2023     November 2023	\$7,047 \$9,443 \$3,452 \$14,179	(\$410)		\$14,272	044000	v: · /	94.91%
April 2023 May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023	\$9,443 \$3,452 \$14,179	, ,	-5.81%		\$14,680	(\$408)	97.21%
May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023	\$3,452 \$14,179	(\$145)		\$6,637	\$5,661	\$975	117.22%
June 2023 July 2023 August 2023 September 2023 October 2023 November 2023	\$14,179		-1.53%	\$9,299	\$5,076	\$4,223	183.19%
July 2023 August 2023 September 2023 October 2023 November 2023	. ,	(\$117)	-3.39%	\$3,334	\$3,133	\$202	106.43%
August 2023 September 2023 October 2023 November 2023		\$0	0.00%	\$14,179	\$14,348	(\$169)	98.82%
September 2023 October 2023 November 2023	\$8,744	\$0	0.00%	\$8,744	\$8,910	(\$167)	98.12%
October 2023 November 2023	\$0	\$0	N/A	\$0	\$6,073	(\$6,073)	0.00%
November 2023	\$996	\$0	0.00%	\$996	\$1,075	(\$79)	92.64%
	\$905	\$0	0.00%	\$905	\$942	(\$38)	95.98%
December 2023	\$2,291	\$0	0.00%	\$2,291	\$3,483	(\$1,193)	65.75%
	\$1,224	\$0	0.00%	\$1,224	\$768	\$456	159.36%
January 2024	\$288	\$0	0.00%	\$288	\$532	(\$244)	54.10%
February 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
March 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
April 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
May 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
June 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
July 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
August 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
September 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
October 2024	\$0	\$0	N/A	\$0	\$0	\$0	N/A
Cumulative Totals	\$444,414	(\$15,427)	-3.47%	\$428,987	\$433,986	(\$4,999)	98.84%
00% Limited Cumulative Total							N/A
'					Minim	um Completeness (%)	99.00%



#### **Non-Vendor VAS**

		Table 5V — AmeriHealth	Caritas Louisian	a Non-Vendor VAS			
Paid Month	Monthly Encounter Total (FAC Reported)	Monthly Encounter Total (Adjustments)	Percentage of Encounters Adjusted	Monthly Encounter Net Total	CDJ Monthly Reported Total	Monthly Variance	Monthly Completion Percentage
November 2022	\$216,094	(\$1,123)	-0.51%	\$214,972	\$220,116	(\$5,145)	97.66%
December 2022	\$224,658	(\$897)	-0.39%	\$223,761	\$227,458	(\$3,697)	98.37%
January 2023	\$318,803	(\$32,003)	-10.03%	\$286,799	\$290,525	(\$3,726)	98.71%
February 2023	\$308,062	(\$39,157)	-12.71%	\$268,906	\$283,691	(\$14,785)	94.78%
March 2023	\$277,887	(\$16,744)	-6.02%	\$261,143	\$274,545	(\$13,402)	95.11%
April 2023	\$257,177	(\$17,071)	-6.63%	\$240,107	\$251,337	(\$11,230)	95.53%
May 2023	\$325,338	(\$25,389)	-7.80%	\$299,949	\$345,400	(\$45,451)	86.84%
June 2023	\$274,851	(\$13,597)	-4.94%	\$261,254	\$273,865	(\$12,611)	95.39%
July 2023	\$363,546	(\$17,850)	-4.90%	\$345,696	\$362,475	(\$16,779)	95.37%
August 2023	\$342,868	(\$21,603)	-6.30%	\$321,265	\$332,466	(\$11,201)	96.63%
September 2023	\$303,941	(\$9,489)	-3.12%	\$294,452	\$309,561	(\$15,109)	95.11%
October 2023	\$332,125	(\$4,939)	-1.48%	\$327,186	\$318,650	\$8,536	102.67%
November 2023	\$296,735	(\$6,918)	-2.33%	\$289,817	\$311,382	(\$21,565)	93.07%
December 2023	\$290,917	(\$4,487)	-1.54%	\$286,430	\$325,612	(\$39,182)	87.96%
January 2024	\$245,100	(\$2,146)	-0.87%	\$242,954	\$263,631	(\$20,677)	92.15%
February 2024	\$425,793	(\$7,814)	-1.83%	\$417,979	\$425,867	(\$7,888)	98.14%
March 2024	\$206,023	(\$2,052)	-0.99%	\$203,971	\$211,109	(\$7,139)	96.61%
April 2024	\$272,159	(\$2,137)	-0.78%	\$270,022	\$275,284	(\$5,262)	98.08%
May 2024	\$351,703	(\$17,975)	-5.11%	\$333,728	\$348,151	(\$14,423)	95.85%
June 2024	\$304,213	(\$20,983)	-6.89%	\$283,230	\$284,547	(\$1,316)	99.53%
July 2024	\$315,108	(\$8,588)	-2.72%	\$306,520	\$310,176	(\$3,656)	98.82%
August 2024	\$281,275	(\$708)	-0.25%	\$280,567	\$274,094	\$6,473	102.36%
September 2024	\$275,080	(\$2,133)	-0.77%	\$272,948	\$284,174	(\$11,227)	96.04%
October 2024	\$310,802	(\$1,525)	-0.49%	\$309,277	\$325,717	(\$16,440)	94.95%
Cumulative Totals	\$7,120,257	(\$277,327)	-3.89%	\$6,842,931	\$7,129,832	(\$286,901)	95.97%
100% Limited Cumulative Total							N/A
	·				Minim	um Completeness (%)	99.00%
						Non-Compliant	-3.03%



# **Appendix B: Definitions and Acronyms**

The following terms are used throughout this document:

**Cash Disbursement Journal (CDJ)** – A record of payments from an MCO or delegated vendor to service providers for a given month as reported by the MCO to the Louisiana Department of Health (LDH).

**DXC Technology (DXC)** – State fiscal agent contractor prior to October 1, 2020. In 2020, DXC was sold to Veritas Capital and ultimately formed a new company, Gainwell Technologies.

**Fiscal Agent Contractor (FAC)** – A contractor selected to design, develop and maintain the Medicaid Management Information System (MMIS); Gainwell is the current FAC.

**Gainwell Technologies (Gainwell)** – Current State fiscal agent contractor. Formerly known as DXC Technology.

Healthy Louisiana - The name of Louisiana's Medicaid managed care program as of May 2016.

**Louisiana Department of Health (LDH)** – The agency in charge of overseeing the health services for the citizens of the state of Louisiana.

Managed Care Organization (MCO) – A private organization that has entered into a risk-based contractual arrangement with LDH to obtain and finance care for enrolled Medicaid or Louisiana Children's Health Insurance Program (LaCHIP) members. MCOs receive a capitation, or per member per month (PMPM), payment from LDH for each enrolled member. During the reporting period, six MCOs were operating in Louisiana. They are Healthy Blue – formerly Amerigroup Louisiana, Inc., AmeriHealth Caritas Louisiana (ACLA), Louisiana Healthcare Connections (LHCC), Aetna Better Health of Louisiana (Aetna), UnitedHealthcare Community Plan (UHC), and Humana Healthy Horizons in Louisiana (Humana).

**Medicaid Management Information System (MMIS)** – The claims and encounter processing system used by the FAC. MCO submitted encounters are loaded into this system and assigned a unique claim identifier.

**Value-Added Services (VAS)** – A covered service provided by the MCO to its members that is currently a non-covered service in the state's fee-for-service plan, for which the MCO received no additional capitated payment. Also known as Expanded Services.



The following terms are used in the monthly tables throughout this document:

**100% Limited Completion** - When an individual vendor's cumulative completion percentage exceeds 100 percent, the encounter total is decreased by the variance between the encounter and cash disbursement journal payment amounts. This results in a limited cumulative completion percentage of 100%. For the entire plan, (Tables 1 and 1V), the limited cumulative completion percentage is calculated using the adjusted encounter amounts of all limited vendor and non-vendor results. This adjustment is to ensure that the entire plan completion percentage is not over-stated.

**CDJ Monthly Reported Total** – The sum of all payments from an MCO or delegated vendor to service providers for the reconciliation period reported in the Cash Disbursement Journal (CDJ).

**Monthly Completion Percentage** – The "Monthly Encounter Net Total" divided by "CDJ Monthly Reported Total".

**Monthly Encounter Net Total** – The difference between the "Monthly Encounter Total (FAC Reported)" and "Monthly Encounter Total (Adjustments)".

**Monthly Encounter Total (Adjustments)** – Total paid amount of encounters identified as denied, calculated void or potential duplicate.

- State System Denied Encounter A submitted encounter that is paid by the plan but is denied by the Fiscal Agent Contractor (FAC) due to MMIS Claims Subsystem edits.
- Health Plan Denied Encounter A submitted encounter that is denied by the plan.
   This denied encounter is indicated by a value of 'D' in the second position of the MCO ICN submitted by the plan.
- Calculated Voids A pair of paid encounters having the same base patient account number or plan internal control number (ICN) if applicable. One of the encounters may appear to be a replacement of the other without a corresponding void encounter transaction being present. In this case, an adjustment is made to account for the missing void transaction. The magnitude of this adjustment depends upon the plans' response to a listing of potential calculated void encounters.
- Duplicate Encounters A pair of paid encounters having identically-billed fields that appear to be duplicates of one another. One of these encounters may be excluded from the analysis depending upon the plans' response to a listing of potential duplicate encounters.

**Monthly Encounter Total (FAC Reported)** – The sum of all paid amounts on encounters submitted to the MMIS.

**Monthly Variance** – The difference between the "Monthly Encounter Net Total" and the "CDJ Monthly Reported Total".

**Percentage of Encounters Adjusted** – The "Monthly Encounter Total (Adjustments)" divided by "Monthly Encounter Total (FAC Reported)".



# **Appendix C: Analysis**

Encounters from institutional, medical and pharmacy claim types were combined on like data fields. We analyzed the line reported information of each encounter to capture the amount paid on the entire claim. Encounter totals were calculated by summarizing the data by the MCO paid date, MCO identification number (ID) and specific delegated vendor criteria. MCO submitted cash disbursements were summarized by paid date, MCO ID and specific delegated vendor criteria to create a matching table. These matching tables were combined using common fields between the tables and were used to produce the results.

Based on criteria provided by the MCO, we identified ACLA encounters as follows:

Active Vendors							
Vendor Type	Vendor Name	Identified By	Notes				
Non-Emergency Medical Transportation (NEMT)	Southeastrans	Characters 3 and 4 of Plan ICN contain "SE"					
Pharmacy Benefits	Prime Therapeutics	Claim type code of '12' Characters 3 and 4 of Plan ICN contain "PB" Dates of service beginning on October 28, 2023	Formerly known as Magellan Rx prior to January 2025 report				
Non-Vendor	ACLA	All other plan submitted encounters					

Inactive Vendors							
Vendor Type	Vendor Name	Identified By	Notes				
Vision Services	VSP	Characters 2 and 3 of Plan ICN contain "VV" Characters 3 and 4 of Plan ICN contain "VV"	Replaced by Avesis Vision – Effective January 1, 2020				
Dental Services	DINA Dental	Characters 3 and 4 of Plan ICN contain "DD"	Replaced by Avesis Dental – Effective January 1, 2020				
Dental Services	Avesis Dental	Characters 3 and 4 of Plan ICN contain "AD"	No longer offered – Effective January 1, 2023				
Vision Services	Avesis Vision	Characters 3 and 4 of Plan ICN contain "AV"	Replaced by ACLA – Effective September 1, 2022				
Pharmacy Benefits	PerformRx	Claim type code of '12'	Replaced by Prime Therapeutics – Effective October 28, 2023				



# **Appendix D: Data Analysis Assumptions**

- This analysis is performed on encounter data that was submitted by the MCOs to the FAC and loaded into the FAC MMIS. Encounters submitted by any MCO that were rejected by the FAC for errors in submission or other reasons are not transmitted to Myers and Stauffer LC.
- For the purposes of this study, the payment amounts associated with denied encounters are identified as zero dollars in the encounter reconciliation analysis since they bear no impact on cash disbursements.
- 3. A voiding encounter has the same paid date as the original/voided encounter, which may differ from when the void or adjustment occurred. Therefore, the voiding encounters were coded to match the adjustment claim's paid date to allow for the proper matching of cash disbursements that occurred due to these void transactions. However, we were unable to reallocate the void encounters in which there was not an associated adjustment claim.
- 4. CDJ and encounter payments are analyzed to ensure that positive and negative payments correspond to the record's transaction type. For example, a void should have a negative amount. Additionally, the payment's amount on void and back-out encounters should match the amount on the encounter being adjusted. If detected, the payment is adjusted to the appropriate sign or amount.
- 5. We instructed the MCOs to exclude referral fees, management fees, and other non-encounter related fees from the CDJ data that is submitted to Myers and Stauffer LC. We reviewed the CDJs for these payments and removed them from the analysis when they were identified.
- Separately itemized interest expenses are excluded from the CDJ and encounter totals when the interest amounts are included in the MCO paid amounts on the encounters and/or CDJ transactions.
- 7. Due to rounding, the sum of the displayed percentages in this report may not add up to the total.
- 8. The short run-out period for encounter submissions may not allow sufficient time for the MCOs to resolve encounter submission issues noted in previous reconciliation reports. This may result in lower completion percentages when reconciling the encounters to CDJ totals.
- 9. Opportunities for improving the encounter reconciliation process have been identified during analysis of the encounter data and cash disbursement journals, as well as frequent interactions with the MCOs, their delegated vendors, LDH, and the FAC. While we have attempted to account for these situations, other potential issues within the data may exist that have not yet been identified which may require us to restate a report or modify reconciliation processes in the future.